Taiwan Genomic Industry Alliance inc. (TGIA) – A Taiwanese company located in Nankang Software Park as a business center, which was established under the guidance of the “Asia Pacific Biomedical Silicon Valley Precision Medicine Program ”operated by the National Health Research Institutes (NHRI) in 2017 and was approved to be officially stationed in the Hsinchu Biomedical Science Park as an operational headquarter and the R&D center in 2022. Through the collaboration and technical transfer from the NHRI, we are able to build the database contain rare disease-related genetic variants, cancer variants, and phenotypes of Asians, which could vigorously promote the research and improve health outcomes, thereby, benefit for the precision medicine development. TGIA also build the most advanced next-generation and third generation high throughput industrial-grade sequencing laboratory in Taiwan, including Illumina Novaseq 6000 and Pacbio Sequel IIe, capable of providing high quality sequencing service. We anticipate to become the leading company in the field of disease, genetics and cancer genetics sequencing, and become an important medical hub in the Asia-Pacific region under the cooperation with the medical centers.
Core Competence
- Industry-Academia Collaboration and Technology Transfer from NHRI
- High throughput industrial-grade sequencing laboratory for long reads and short reads sequencing
- Hardware accelerated and intelligent computing
- CE-IVD certified AI-driven gene interpretation platform
- Strategic collaboration with medical centers and academic units
- Asian population disease genetic variants database
